vs
Side-by-side financial comparison of PARK NATIONAL CORP (PRK) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
PARK NATIONAL CORP is the larger business by last-quarter revenue ($168.3M vs $129.7M, roughly 1.3× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 2.2%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 4.9%).
National Retail Systems, Inc. (NRS) includes Keystone Freight Corp. & National Retail Transportation, Inc. (NRT). NRS is an asset based 3PL founded in 1952. It is headquartered in Lyndhurst, New Jersey, United States.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
PRK vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.3M | $129.7M |
| Net Profit | $42.6M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | — | -25.0% |
| Net Margin | 25.3% | — |
| Revenue YoY | 2.2% | 73.4% |
| Net Profit YoY | 10.4% | — |
| EPS (diluted) | $2.62 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.3M | $129.7M | ||
| Q3 25 | $169.5M | $164.9M | ||
| Q2 25 | $168.7M | $114.4M | ||
| Q1 25 | $157.9M | $81.7M | ||
| Q4 24 | $164.7M | $74.8M | ||
| Q3 24 | $170.3M | $62.9M | ||
| Q2 24 | $157.7M | $54.1M | ||
| Q1 24 | $152.8M | $41.4M |
| Q4 25 | $42.6M | — | ||
| Q3 25 | $47.2M | $25.7M | ||
| Q2 25 | $48.1M | $-12.8M | ||
| Q1 25 | $42.2M | $-41.2M | ||
| Q4 24 | $38.6M | — | ||
| Q3 24 | $38.2M | $-54.8M | ||
| Q2 24 | $39.4M | $-70.4M | ||
| Q1 24 | $35.2M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | — | -25.0% | ||
| Q3 25 | 34.3% | 15.1% | ||
| Q2 25 | 35.2% | -11.1% | ||
| Q1 25 | 32.4% | -52.2% | ||
| Q4 24 | — | -81.2% | ||
| Q3 24 | 27.4% | -89.3% | ||
| Q2 24 | 30.6% | -125.1% | ||
| Q1 24 | 27.8% | -336.5% |
| Q4 25 | 25.3% | — | ||
| Q3 25 | 27.8% | 15.6% | ||
| Q2 25 | 28.5% | -11.1% | ||
| Q1 25 | 26.7% | -50.4% | ||
| Q4 24 | 23.5% | — | ||
| Q3 24 | 22.4% | -87.1% | ||
| Q2 24 | 25.0% | -130.1% | ||
| Q1 24 | 23.0% | -328.9% |
| Q4 25 | $2.62 | $0.04 | ||
| Q3 25 | $2.92 | $0.28 | ||
| Q2 25 | $2.97 | $-0.14 | ||
| Q1 25 | $2.60 | $-0.47 | ||
| Q4 24 | $2.38 | $-0.71 | ||
| Q3 24 | $2.35 | $-0.70 | ||
| Q2 24 | $2.42 | $-0.91 | ||
| Q1 24 | $2.17 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $233.5M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $114.8M |
| Total Assets | $9.8B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $233.5M | $93.0M | ||
| Q3 25 | $218.9M | $110.9M | ||
| Q2 25 | $193.1M | $75.2M | ||
| Q1 25 | $237.6M | $61.9M | ||
| Q4 24 | $160.6M | $58.5M | ||
| Q3 24 | $201.7M | $36.4M | ||
| Q2 24 | $261.5M | $32.3M | ||
| Q1 24 | $306.1M | $43.3M |
| Q4 25 | $1.4B | $114.8M | ||
| Q3 25 | $1.3B | $73.6M | ||
| Q2 25 | $1.3B | $32.7M | ||
| Q1 25 | $1.3B | $32.8M | ||
| Q4 24 | $1.2B | $59.1M | ||
| Q3 24 | $1.2B | $-30.5M | ||
| Q2 24 | $1.2B | $15.1M | ||
| Q1 24 | $1.2B | $74.1M |
| Q4 25 | $9.8B | $605.2M | ||
| Q3 25 | $9.9B | $538.6M | ||
| Q2 25 | $9.9B | $555.3M | ||
| Q1 25 | $9.9B | $548.8M | ||
| Q4 24 | $9.8B | $594.1M | ||
| Q3 24 | $9.9B | $504.4M | ||
| Q2 24 | $9.9B | $551.1M | ||
| Q1 24 | $9.9B | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $198.3M | $60.7M |
| Free Cash FlowOCF − Capex | $191.9M | — |
| FCF MarginFCF / Revenue | 114.1% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | 4.65× | — |
| TTM Free Cash FlowTrailing 4 quarters | $328.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $198.3M | $60.7M | ||
| Q3 25 | $52.6M | $14.3M | ||
| Q2 25 | $49.7M | $5.0M | ||
| Q1 25 | $37.9M | $-42.2M | ||
| Q4 24 | $178.8M | $-35.7M | ||
| Q3 24 | $43.8M | $-42.5M | ||
| Q2 24 | $50.9M | $-40.2M | ||
| Q1 24 | $35.0M | $-119.0M |
| Q4 25 | $191.9M | — | ||
| Q3 25 | $51.1M | $14.2M | ||
| Q2 25 | $48.4M | — | ||
| Q1 25 | $36.8M | — | ||
| Q4 24 | $169.7M | — | ||
| Q3 24 | $41.7M | — | ||
| Q2 24 | $49.0M | $-40.3M | ||
| Q1 24 | $31.9M | — |
| Q4 25 | 114.1% | — | ||
| Q3 25 | 30.1% | 8.6% | ||
| Q2 25 | 28.7% | — | ||
| Q1 25 | 23.3% | — | ||
| Q4 24 | 103.0% | — | ||
| Q3 24 | 24.5% | — | ||
| Q2 24 | 31.1% | -74.5% | ||
| Q1 24 | 20.8% | — |
| Q4 25 | 3.8% | — | ||
| Q3 25 | 0.9% | 0.1% | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 5.6% | — | ||
| Q3 24 | 1.2% | 0.0% | ||
| Q2 24 | 1.2% | 0.2% | ||
| Q1 24 | 2.1% | 0.0% |
| Q4 25 | 4.65× | — | ||
| Q3 25 | 1.11× | 0.56× | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 0.90× | — | ||
| Q4 24 | 4.63× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | 0.99× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRK
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
